Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16176333 | 1.00 | POLB (0.33) | POLBNPC1RAB9AATM | |
| SCHEMBL16188979 | 0.85 | POLB (0.33) | POLBNPC1RAB9AATM | |
| SCHEMBL10773328 | 0.79 | POLB (0.39) | POLBNPC1RAB9AATM | |
| SCHEMBL17523413 | 0.79 | NPC1 (0.31) | POLBNPC1RAB9AATM | |
| SCHEMBL21428120 | 0.78 | ATM (0.37) | POLBNPC1RAB9AATM | |
| SCHEMBL7611640 | 0.74 | TGFBR1 (0.39) | POLBNPC1RAB9AATM | |
| SCHEMBL2857868 | 0.72 | — | — | |
| SCHEMBL6036407 | 0.71 | POLB (0.35) | POLBNPC1RAB9AATM | |
| SCHEMBL4696449 | 0.71 | POLB (0.35) | POLBNPC1RAB9AATM | |
| SCHEMBL21916061 | 0.71 | POLB (0.30) | POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3545956-B1 | 3,5-(UN)SUBSTITUTED-1H-PYRROLO[2,3-B]PYRIDINE, 1H-PYRAZOLO[3,4-B]PYRIDINE AND 5H- PYRROLO[2,3-B]PYRAZINE DUAL ITK AND JAK3 KINASE INHIBITORS | ARRIEN PHARMACEUTICALS LLC (US) | 2020-12-16 | — | — | EP | disclosed |
| EP-3545956-B1 | 3,5-(UN)SUBSTITUTED-1H-PYRROLO[2,3-B]PYRIDINE, 1H-PYRAZOLO[3,4-B]PYRIDINE AND 5H- PYRROLO[2,3-B]PYRAZINE DUAL ITK AND JAK3 KINASE INHIBITORS | ARRIEN PHARMACEUTICALS LLC (US) | 2020-12-16 | — | — | EP | disclosed |
| EP-3545956-A1 | 3,5-(UN)SUBSTITUTED-1H-PYRROLO[2,3-B]PYRIDINE, 1H-PYRAZOLO[3,4-B]PYRIDINE AND 5H- PYRROLO[2,3-B]PYRAZINE DUAL ITK AND JAK3 KINASE INHIBITORS | Arrien Pharmaceuticals LLC (US) | 2019-10-02 | — | — | EP | disclosed |
| EP-3545956-A1 | 3,5-(UN)SUBSTITUTED-1H-PYRROLO[2,3-B]PYRIDINE, 1H-PYRAZOLO[3,4-B]PYRIDINE AND 5H- PYRROLO[2,3-B]PYRAZINE DUAL ITK AND JAK3 KINASE INHIBITORS | Arrien Pharmaceuticals LLC (US) | 2019-10-02 | — | — | EP | disclosed |
| EP-2986300-B1 | 3,5-(UN)SUBSTITUTED-1H-PYRROLO[2,3-B]PYRIDINE, 1H-PYRAZOLO[3,4-B]PYRIDINE AND 5H-PYRROLO [2-,3-B]PYRAZINE DUAL ITK AND JAK3 KINASE INHIBITORS | ARRIEN PHARMACEUTICALS LLC (US) | 2019-06-26 | — | — | EP | disclosed |
| US-9834551-B2 | Substituted pyrrolo[2,3-b]pyrazines and substituted pyrazolo[3,4-b]pyridines as ITK and JAK kinase inhibitors | ARRIEN PHARMACEUTICALS LLC (US) | 2017-12-05 | — | — | US | disclosed |
| US-9834551-B2 | Substituted pyrrolo[2,3-b]pyrazines and substituted pyrazolo[3,4-b]pyridines as ITK and JAK kinase inhibitors | ARRIEN PHARMACEUTICALS LLC (US) | 2017-12-05 | — | — | US | disclosed |
| US-9834551-B2 | Substituted pyrrolo[2,3-b]pyrazines and substituted pyrazolo[3,4-b]pyridines as ITK and JAK kinase inhibitors | ARRIEN PHARMACEUTICALS LLC (US) | 2017-12-05 | — | — | US | disclosed |
| US-20160046627-A1 | ITK and JAK Kinase Inhibitors | ARRIEN PHARMACEUTICALS LLC | 2016-02-18 | — | — | US | disclosed |
| US-20160046627-A1 | ITK and JAK Kinase Inhibitors | ARRIEN PHARMACEUTICALS LLC | 2016-02-18 | — | — | US | disclosed |
| US-20160046627-A1 | ITK and JAK Kinase Inhibitors | ARRIEN PHARMACEUTICALS LLC | 2016-02-18 | — | — | US | disclosed |
| US-9206188-B2 | Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors | ARRIEN PHARMACEUTICALS LLC (US) | 2015-12-08 | — | — | US | disclosed |
| US-9206188-B2 | Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors | ARRIEN PHARMACEUTICALS LLC (US) | 2015-12-08 | — | — | US | disclosed |
| US-9206188-B2 | Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors | ARRIEN PHARMACEUTICALS LLC (US) | 2015-12-08 | — | — | US | disclosed |
| US-20140315909-A1 | 3,5-(Un)substituted-1H-pyrrolo[2,3-b]pyridine, 1H-pyrazolo[3,4-b]pyridine and 5H- pyrrolo[2,3-b]pyrazine dual ITK and JAK3 Kinase Inhibitors | ARRIEN PHARMACEUTICALS LLC (US) | 2014-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160046627-A1 | ITK and JAK Kinase Inhibitors | JAK3, ITK, JAK2 | POLB 1243/4885NPC1 3400/4885RAB9A 2038/4885 |
| US-20140315909-A1 | 3,5-(Un)substituted-1H-pyrrolo[2,3-b]pyridine, 1H-pyrazolo[3,4-b]pyridine and 5H- pyrrolo[2,3-b]pyrazine dual ITK and JAK3 Kinase Inhibitors | JAK3, TYK2, JAK2 | POLB 1281/4885NPC1 4029/4885RAB9A 2945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.